Literature DB >> 16107258

An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen.

Aaron Patton1, Michael C Mullenix, Steven J Swanson, Eugen Koren.   

Abstract

Bridging Enzyme-Linked Immunosorbent Assay (ELISA) is commonly used in detection of antibodies directed against therapeutic proteins. Advantages of the bridging ELISA include the capability to detect antibodies regardless of their isotype or the species of origin. However, detection of antibodies can be difficult, if not impossible, in the presence of high levels of the antigen in the sample matrix. This protocol describes a bridging ELISA that uses a covalently coupled high density antigen surface combined with an acid dissociation step to allow for antibody detection in the presence of antigen in human serum.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16107258     DOI: 10.1016/j.jim.2005.06.014

Source DB:  PubMed          Journal:  J Immunol Methods        ISSN: 0022-1759            Impact factor:   2.303


  35 in total

Review 1.  Immunogenicity to therapeutic proteins: impact on PK/PD and efficacy.

Authors:  Narendra Chirmule; Vibha Jawa; Bernd Meibohm
Journal:  AAPS J       Date:  2012-03-10       Impact factor: 4.009

Review 2.  Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.

Authors:  Denise M O'Hara; Valerie Theobald; Adrienne Clements Egan; Joel Usansky; Murli Krishna; Julie TerWee; Mauricio Maia; Frank P Spriggs; John Kenney; Afshin Safavi; Jeannine Keefe
Journal:  AAPS J       Date:  2012-03-14       Impact factor: 4.009

3.  Ligand binding assays in the 21st Century laboratory: platforms.

Authors:  Franklin P Spriggs; Zhandong Don Zhong; Afshin Safavi; Darshana Jani; Narasaiah Dontha; Anita Kant; Jenny Ly; Lia Brilando; Karolina Österlund; Nathalie Rouleau; Saloumeh Kadkhodayan Fischer; Martin Boissonneault; Chad Ray
Journal:  AAPS J       Date:  2012-03       Impact factor: 4.009

Review 4.  Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology Perspective.

Authors:  Yow-Ming C Wang; Jie Wang; Yuen Yi Hon; Lin Zhou; Lanyan Fang; Hae Young Ahn
Journal:  AAPS J       Date:  2015-12-31       Impact factor: 4.009

Review 5.  Antidrug antibody assay validation: industry survey results.

Authors:  Boris Gorovits
Journal:  AAPS J       Date:  2009-03-03       Impact factor: 4.009

Review 6.  Practical considerations for nonclinical safety evaluation of therapeutic monoclonal antibodies.

Authors:  Carmel M Lynch; Bruce W Hart; Iqbal S Grewal
Journal:  MAbs       Date:  2009 Jan-Feb       Impact factor: 5.857

7.  Immunogenicity of antibody drug conjugates: bioanalytical methods and monitoring strategy for a novel therapeutic modality.

Authors:  M Benjamin Hock; Karen E Thudium; Montserrat Carrasco-Triguero; Nikolai F Schwabe
Journal:  AAPS J       Date:  2014-11-08       Impact factor: 4.009

8.  Stratification of antibody-positive subjects by antibody level reveals an impact of immunogenicity on pharmacokinetics.

Authors:  Lei Zhou; Sarah A Hoofring; Yu Wu; Thuy Vu; Peiming Ma; Steven J Swanson; Narendra Chirmule; Marta Starcevic
Journal:  AAPS J       Date:  2012-10-09       Impact factor: 4.009

9.  Practical application of acid dissociation in monitoring patients treated with adalimumab.

Authors:  Francisca Llinares-Tello; José Rosas-Gómez de Salazar; José Miguel Senabre-Gallego; Gregorio Santos-Soler; Carlos Santos-Ramírez; Esteban Salas-Heredia; Xavier Barber-Vallés; Juan Molina-García
Journal:  Rheumatol Int       Date:  2014-05-10       Impact factor: 2.631

10.  Recommendations for the Assessment and Management of Pre-existing Drug-Reactive Antibodies During Biotherapeutic Development.

Authors:  Li Xue; Adrienne Clements-Egan; Lakshmi Amaravadi; Mary Birchler; Boris Gorovits; Meina Liang; Heather Myler; Shobha Purushothama; Marta Starcevic Manning; Crystal Sung
Journal:  AAPS J       Date:  2017-11-06       Impact factor: 4.009

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.